Evidence map›Paper›PMID 40474836›Full record

ArticleFuture oncology (London, England)2025

Testing the accuracy of a three-miRNA panel for the detection of primary prostate cancer: a discovery and validation study.

Wuping Wang, Pengwu Zhang, Zhenjian Ge, Wenkang Chen, Yingqi Li, Shengjie Lin, Yutong Wu, Siwei Chen, Huimei Zhou, Xutai Li and 3 more

Abstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Wuping WangDepartment of Urology, Peking University Shenzhen Hospital, Shenzhen, China.
Pengwu ZhangDepartment of Urology, Peking University Shenzhen Hospital, Shenzhen, China.
Zhenjian GeDepartment of Urology, Peking University Shenzhen Hospital, Shenzhen, China.
Wenkang ChenDepartment of Urology, Peking University Shenzhen Hospital, Shenzhen, China.
Yingqi LiDepartment of Urology, Peking University Shenzhen Hospital, Shenzhen, China.
Shengjie LinDepartment of Urology, Peking University Shenzhen Hospital, Shenzhen, China.
Yutong WuDepartment of Urology, Peking University Shenzhen Hospital, Shenzhen, China.
Siwei ChenDepartment of Urology, Peking University Shenzhen Hospital, Shenzhen, China.
Huimei ZhouDepartment of Urology, Peking University Shenzhen Hospital, Shenzhen, China.
Xutai LiDepartment of Urology, Peking University Shenzhen Hospital, Shenzhen, China.
Lingzhi TaoDepartment of Urology, Peking University Shenzhen Hospital, Shenzhen, China.
Yongqing LaiDepartment of Urology, Peking University Shenzhen Hospital, Shenzhen, China.
Liangchao NiDepartment of Urology, Peking University Shenzhen Hospital, Shenzhen, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe harm that prostate cancer inflicts on humans is becoming increasingly grave, imposing a tremendous burden and impact on patients and society. While PSA(Prostate-specific antigen) is commonly used for prostate cancer screening, its high rates of false positives and false negatives can lead to misdiagnosis (unnecessary prostate biopsies) or missed diagnoses (delayed treatment), with potentially serious consequences. Thus, there is a critical need for alternative diagnostic methods to overcome the limitations of PSA. This study aims to identify a novel panel of miRNAs as biomarkers for the diagnosis of prostate cancer. MATERIALS AND

methodThis study was carried out in three phases. The diagnostic potential of serum miRNA was assessed by analyzing the area under the ROC curve (AUC).

resultWe developed three miRNA panels (miR-200c-3p, miR-221-3p, and miR-20a-5p), which significantly improved the diagnostic accuracy.

conclusionThe three miRNA panels demonstrate substantial diagnostic potential for prostate cancer and are anticipated to help reduce the high false positive and false negative rates commonly seen with PSA testing.

Indexed as

Biomarkers, TumorMicroRNAsProstatic NeoplasmsAgedEarly Detection of CancerHumansMaleMiddle AgedProstate-Specific AntigenROC CurveBiomarkers, TumorMicroRNAsMIR221, humanMIRN200 microRNA, humanProstate-Specific AntigenbiomarkermiRNAProstate cancerPSAscreeningserumtarget gene

Identifiers

PMID40474836
PMCPMC12239789

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.